FGL (FG Loop Peptide)

1. Overview

FGL (FG Loop peptide) is a 15-amino acid synthetic peptide derived from the second fibronectin type III (FnIII) module of neural cell adhesion molecule (NCAM). The peptide sequence EVYVVAENQQGKSKA corresponds to the FG loop region within this domain -- the specific structural element through which NCAM interacts with and activates fibroblast growth factor receptor 1 (FGFR1) [1][9]. By mimicking this interaction, FGL functions as a direct FGFR1 agonist, independent of the full NCAM protein, activating downstream signaling cascades that promote neuronal survival, neurite outgrowth, synaptogenesis, and anti-inflammatory responses [1][3].

NCAM is one of the most abundant cell adhesion molecules in the nervous system, mediating cell-cell and cell-matrix interactions critical for neurodevelopment, synaptic plasticity, and neural repair. The discovery that a small peptide fragment from NCAM could independently activate FGFR1 signaling represented an important advance in molecular neuroscience, as it provided a tractable pharmacological tool for harnessing NCAM-FGFR signaling without the complexity of full-length NCAM or its multiple isoforms [10][17].

FGL was developed primarily through the work of the Bhatt laboratory and collaborators at the University of Copenhagen and ENKAM Pharmaceuticals. Preclinical studies have demonstrated that FGL crosses the blood-brain barrier after subcutaneous administration and produces robust neuroprotective and cognitive-enhancing effects in multiple disease models, including Alzheimer's disease, traumatic brain injury, stroke, and age-related cognitive decline [2][3][5][7].

Full Name

FG Loop peptide (NCAM FnIII module 2)

Sequence

EVYVVAENQQGKSKA (15 amino acids)

Molecular Weight

Approximately 1620 Da

Source

Derived from neural cell adhesion molecule (NCAM) second FnIII domain FG loop

Target

Fibroblast growth factor receptor 1 (FGFR1)

Mechanism

FGFR1 agonist; activates PLCgamma, MAPK/ERK, and PI3K/Akt pathways

Key Effects

Neurite outgrowth, synaptogenesis, neuroprotection, memory enhancement

BBB Penetration

Crosses blood-brain barrier after systemic (subcutaneous/intraperitoneal) administration

Primary Developers

Bhatt lab and Bhatt/Bhatt labs, University of Copenhagen / ENKAM Pharmaceuticals

Regulatory Status

Investigational; preclinical stage

2. Mechanism of Action

2.1 FGFR1 Activation

FGL binds directly to the extracellular domain of FGFR1, mimicking the binding interaction of the second FnIII module of NCAM [1][9]. This binding activates FGFR1 tyrosine kinase activity, triggering three major intracellular signaling cascades:

PLCgamma pathway. FGFR1 phosphorylates and activates phospholipase C gamma (PLCgamma), which hydrolyzes PIP2 to generate IP3 and DAG. IP3 triggers calcium release from intracellular stores, activating CaMKII (calcium/calmodulin-dependent protein kinase II), which is critical for long-term potentiation (LTP) and memory consolidation [4].

MAPK/ERK pathway. FGFR1 activation leads to Ras-Raf-MEK-ERK signaling, promoting neurite outgrowth, synaptic protein expression, and neuronal differentiation. ERK activation also phosphorylates CREB (cAMP response element-binding protein), a transcription factor essential for long-term memory formation.

PI3K/Akt pathway. FGFR1 activates phosphoinositide 3-kinase (PI3K), which generates PIP3 and activates Akt (protein kinase B). This pathway promotes neuronal survival by phosphorylating and inactivating pro-apoptotic proteins (Bad, Bax) and activating anti-apoptotic Bcl-2 family members [6][18].

2.2 Anti-Inflammatory Effects

FGL suppresses neuroinflammation through FGFR-dependent modulation of microglial activation [6][20]. In LPS-stimulated microglia, FGL reduces production of nitric oxide (NO), IL-1beta, and TNF-alpha through PI3K/Akt-mediated inhibition of NF-kappaB signaling. FGL also shifts microglial phenotype from the pro-inflammatory M1 state toward the neuroprotective M2 state, characterized by increased production of anti-inflammatory cytokines (IL-10, TGF-beta) and neurotrophic factors (BDNF, IGF-1) [20].

2.3 Synaptic Enhancement

FGL increases synaptic density and strength through multiple mechanisms [2][8]:

• Increased dendritic spine density: FGL promotes formation of mushroom-type (mature) dendritic spines in hippocampal CA1 neurons, increasing spine density by approximately 25% [8]
• Enhanced presynaptic function: FGL increases synaptic vesicle release probability and upregulates presynaptic markers including synaptophysin and SNAP-25 [2][12]
• LTP enhancement: FGL enhances hippocampal LTP through FGFR-dependent activation of PLCgamma and CaMKII [4]

3. Pharmacokinetics

3.1 FGFR1 Activation Kinetics

FGL's pharmacological activity depends on FGFR1 engagement and downstream signaling kinetics [1][4][11]:

Receptor binding. FGL binds the extracellular immunoglobulin-like domains of FGFR1 at a site that overlaps with but is not identical to the NCAM binding interface. The binding affinity (Kd) has not been precisely published but is estimated in the micromolar range based on cellular activation assays, indicating that FGL is a moderate-affinity agonist compared to FGF ligands [1][16].

Signaling onset. FGFR1 phosphorylation is detectable within minutes of FGL exposure in neuronal cultures. PLCgamma activation occurs within 5-15 minutes, ERK phosphorylation peaks at 15-30 minutes, and Akt activation is sustained for 1-2 hours [1][4].

Transcriptional effects. CREB phosphorylation and subsequent gene transcription (including BDNF, synaptophysin, and other synaptic proteins) occurs over hours, with maximal expression changes at 6-24 hours post-exposure [2][4].

3.2 Blood-Brain Barrier Penetration

A critical pharmacokinetic advantage of FGL is its ability to cross the blood-brain barrier (BBB) after systemic administration [2][3][5]:

Demonstrated BBB penetration. Subcutaneous injection of FGL at 8-10 mg/kg produces measurable pharmacological effects in the hippocampus (increased synaptic density, enhanced LTP, reduced microglial activation), confirming that biologically active concentrations reach the CNS [2][3][5].

Mechanism of BBB crossing. At 1620 Da, FGL exceeds the typical molecular weight cutoff for passive BBB diffusion (~400-500 Da). The peptide may cross the BBB through receptor-mediated transcytosis, adsorptive transcytosis (given its moderately cationic charge from lysine residues), or paracellular transport at regions of BBB permeability. The exact mechanism has not been definitively established [15].

CNS bioavailability. The fraction of systemically administered FGL that reaches the brain has not been quantified. However, the consistent pharmacological effects observed at 8-10 mg/kg subcutaneous doses across multiple research groups and disease models suggest reliable CNS delivery [2][3][5][7].

3.3 Metabolic Stability and Elimination

Peptidase susceptibility. FGL consists entirely of L-amino acids without chemical modifications, making it susceptible to serum and tissue peptidases. The estimated plasma half-life is likely in the range of 30 minutes to 2 hours based on similar-sized unmodified peptides, though published pharmacokinetic data are not available [15].

Route-dependent pharmacokinetics. Subcutaneous administration provides slower absorption and potentially longer exposure than intravenous or intraperitoneal routes, which may be advantageous for sustained FGFR1 activation in the CNS [2][3].

4. Dose-Response Relationship

4.1 In Vitro Dose-Response

FGL demonstrates clear dose-dependent effects in neuronal cultures [1][4][8]:

| Concentration | Effect | System | |---|---|---| | 1 micromolar | Threshold neurite outgrowth stimulation | Primary hippocampal neurons | | 5-10 micromolar | Robust LTP enhancement | Hippocampal slices | | 10 micromolar | Maximal dendritic spine density increase (+25%) | CA1 neurons | | 10-50 micromolar | Anti-inflammatory effects in microglia | Primary microglial cultures |

4.2 In Vivo Dose-Response

| Dose (SC, rodent) | Model | Key Finding | |---|---|---| | 5 mg/kg | Memory (social recognition) | Partial memory enhancement | | 8 mg/kg | Alzheimer's (Tg2576) | Improved spatial memory, reduced neuroinflammation (-40%) | | 8 mg/kg | TBI (CCI) | Lesion volume -35%, improved cognitive outcomes | | 8 mg/kg | Aging (22-month rats) | Restored spatial memory to young adult levels | | 10 mg/kg | Memory (social recognition) | Maximal memory enhancement, +15% synaptic density | | 8 mg/kg | Stroke (MCAO) | Infarct volume -30%, improved neurological scores |

The optimal dose for most applications appears to be 8-10 mg/kg subcutaneous, with doses above 10 mg/kg not showing additional benefit in published studies [2][3][5][7].

4.3 Treatment Duration Effects

The duration of FGL treatment modulates the type of response:

• Single injection (10 mg/kg): Memory enhancement and acute synaptic density increase within 24 hours [2]
• Short course (twice weekly for 3 weeks): Sustained neuroprotection, anti-inflammatory effects, and cognitive restoration in disease models [3][5]
• The distinction between single-dose and repeated-dose effects: suggests that acute FGL activates synaptic plasticity mechanisms, while chronic treatment additionally engages anti-inflammatory and neuroprotective pathways requiring sustained FGFR1 signaling

5. Comparative Effectiveness

5.1 FGL vs. Cerebrolysin

| Parameter | FGL | Cerebrolysin | |---|---|---| | Composition | Single defined peptide (15 AA) | Heterogeneous mixture of peptides/amino acids from porcine brain | | Mechanism | FGFR1 agonist (defined target) | Multiple (neurotrophic, anti-inflammatory; poorly defined) | | BBB penetration | Demonstrated (SC dosing) | Demonstrated (IV dosing) | | Memory enhancement | +15% synaptic density (single dose) | Improved cognitive scores in clinical trials | | AD evidence | Preclinical (Tg2576) | Phase 3 clinical trials (modest benefit) | | Clinical status | Preclinical only | Approved in some countries; not FDA-approved | | Reproducibility | Well-defined; reproducible | Batch-to-batch variability concerns |

FGL's advantage is its defined molecular identity and specific mechanism. Cerebrolysin's advantage is clinical data and regulatory approval in some jurisdictions [3][15].

5.2 FGL vs. BDNF

| Parameter | FGL | BDNF | |---|---|---| | Type | Synthetic peptide (15 AA, ~1.6 kDa) | Neurotrophin protein (119 AA, ~13.5 kDa) | | BBB penetration | Yes (SC administration) | No (too large; requires direct brain injection) | | Mechanism | FGFR1-mediated (upstream of BDNF) | TrkB receptor activation | | Effect on BDNF | Increases BDNF expression | Is BDNF | | Clinical feasibility | Injectable (SC); potential for intranasal | Requires intracerebroventricular delivery | | Neuroprotection | Demonstrated in multiple models | Demonstrated in multiple models |

FGL's principal advantage over direct BDNF therapy is its ability to cross the blood-brain barrier after peripheral administration, whereas BDNF cannot [3][15].

5.3 FGL vs. P21 (CNTF-Derived Peptide)

| Parameter | FGL | P21 | |---|---|---| | Mechanism | FGFR1 agonist | BDNF upregulation + LIF inhibition | | Primary effect | Synaptic enhancement + anti-inflammatory | Neurogenesis + anti-tau | | Route | Subcutaneous | Oral | | BBB penetration | Yes | Yes | | MW | ~1620 Da | ~470 Da | | Memory enhancement | +15% synaptic density | Cognitive rescue in AD models | | AD model efficacy | Improved spatial memory (Tg2576) | Prevented/rescued cognitive deficits (3xTg-AD) | | Oral bioavailability | Unknown | Yes (designed for oral delivery) |

FGL and P21 target different aspects of neurodegeneration -- FGL primarily enhances synaptic function and reduces neuroinflammation, while P21 primarily stimulates neurogenesis and reduces tau pathology. They address complementary pathological processes and could theoretically be combined [3][15].

6. Researched Applications

Memory Enhancement (Strong Preclinical Evidence)

FGL has consistently demonstrated memory-enhancing effects in rodent models. Bhatt et al. (2009) showed that a single subcutaneous injection of FGL (10 mg/kg) enhanced memory consolidation in a social recognition paradigm in rats [2]. The memory-enhancing effect was associated with a 15% increase in hippocampal synaptic contact density and upregulation of presynaptic proteins 24 hours after injection.

Alzheimer's Disease (Preclinical Evidence)

In the Tg2576 transgenic mouse model of Alzheimer's disease, FGL treatment (8 mg/kg subcutaneous, twice weekly for 3 weeks) produced significant improvements in spatial memory assessed by the Morris water maze [3]. Mechanistically, FGL reduced hippocampal microglial activation by approximately 40% and decreased levels of the pro-inflammatory cytokines IL-1beta and TNF-alpha. These findings suggest that FGL's neuroprotective effects in Alzheimer's models are at least partially mediated through anti-inflammatory mechanisms rather than direct effects on amyloid-beta pathology.

Age-Related Cognitive Decline (Preclinical Evidence)

Chronic FGL treatment in aged rats (22 months old) restored hippocampal-dependent spatial memory performance to levels comparable to young adult animals [5]. The cognitive restoration was accompanied by reversal of age-related increases in hippocampal microglial activation and IL-1beta levels, consistent with an anti-neuroinflammatory mechanism of action.

Traumatic Brain Injury (Preclinical Evidence)

FGL (8 mg/kg subcutaneous) administered after controlled cortical impact in rats reduced lesion volume by 35%, decreased perilesional astrogliosis and microglial activation, and improved both sensorimotor and cognitive outcomes at 14 days post-injury [7]. The neuroprotective effect was attributed to combined anti-inflammatory (reduced microglial activation) and anti-apoptotic (Akt-mediated neuronal survival) mechanisms.

Stroke (Preclinical Evidence)

Post-ischemic FGL administration in a middle cerebral artery occlusion (MCAO) rat model reduced infarct volume by approximately 30% and improved neurological deficit scores at 72 hours post-stroke [13]. The mechanism involved both anti-inflammatory effects and direct neuroprotection through the PI3K/Akt survival pathway.

7. Clinical Evidence Summary

8. Dosing in Research

FGL has been investigated exclusively in preclinical models. The most commonly used dose is 8-10 mg/kg administered subcutaneously in rodents. For chronic treatment paradigms (Alzheimer's model, aging), dosing of 8 mg/kg twice weekly for 3 weeks has been employed [3][5]. For acute neuroprotection (TBI, stroke), single or short-course post-injury dosing has been studied [7]. FGL crosses the blood-brain barrier after systemic administration, reaching pharmacologically active concentrations in the hippocampus and cortex.

9. Safety and Side Effects

FGL has been well tolerated in preclinical studies with no reported significant adverse effects at the doses tested (8-10 mg/kg subcutaneous in rodents). As an FGFR1 agonist, theoretical concerns include potential mitogenic effects from sustained FGFR activation. However, FGL activates FGFR1 at physiologically relevant levels rather than producing maximal receptor stimulation, and no evidence of tumorigenesis or abnormal cell proliferation has been reported in preclinical studies.

The peptide's relatively short length (15 amino acids) may limit immunogenic potential, though long-term immunogenicity data are not available. The main limitation of FGL is its peptide nature, which raises questions about metabolic stability and bioavailability that would need to be addressed for clinical development.

Enhanced Safety Considerations

FGFR1 and oncogenesis risk. FGFR1 signaling is implicated in cell proliferation and is amplified or mutated in certain cancers (breast, lung, bladder). Chronic systemic FGFR1 agonism raises a theoretical oncogenesis concern. However, FGL is a partial agonist that activates FGFR1 at physiological rather than supraphysiological levels, and the treatment durations studied (up to 3 weeks) are too short to assess long-term cancer risk. No abnormal cell proliferation has been observed in any preclinical study [1][15][20].

Vascular effects of FGFR activation. FGFR signaling promotes angiogenesis, which could be beneficial in stroke recovery but potentially harmful in the context of tumor vascularization or proliferative diabetic retinopathy. Patients with active malignancies or proliferative vascular conditions would represent theoretical contraindications for FGL therapy [15].

Immunogenicity. FGL is a 15-amino acid peptide derived from a human protein (NCAM), which reduces but does not eliminate immunogenic potential. Repeated subcutaneous administration could theoretically generate anti-FGL antibodies that might cross-react with endogenous NCAM, although this has not been observed in preclinical studies of limited duration [15].

FGFR1 desensitization. Chronic agonist exposure can lead to receptor downregulation or desensitization. If FGL induces FGFR1 internalization or degradation with repeated dosing, efficacy could diminish over time (tachyphylaxis). The twice-weekly dosing protocol used in most studies may partially address this concern by allowing receptor recovery between doses [1][11].

Interaction with FGFR-targeting cancer therapies. Patients receiving FGFR inhibitors (e.g., erdafitinib, futibatinib) for cancer treatment should not receive FGL, as the FGFR agonist and antagonist effects would directly oppose each other.

10. Relationship to NCAM Biology

NCAM exists in three major isoforms (NCAM-180, NCAM-140, and NCAM-120), all sharing the extracellular domain from which FGL is derived [10][17]. NCAM mediates both homophilic (NCAM-NCAM) and heterophilic interactions, with FGFR1 being the best-characterized heterophilic binding partner. The NCAM-FGFR interaction is critical for neurodevelopment, synaptic plasticity, and neural repair.

FGL's therapeutic strategy -- using a minimal peptide fragment to activate a specific signaling interaction of a complex multifunctional molecule -- represents an approach that has been applied to other cell adhesion molecules. The principle that small peptide mimetics of cell adhesion molecule binding domains can serve as pharmacological tools to modulate receptor signaling has broad implications for neuropharmacology.

11. Related Peptides

See also: P21 (CNTF-derived peptide), Semax, Dihexa, Cerebrolysin, Noopept

12. References

1. [1] Bhatt et al. (2004). A synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule binds to and activates fibroblast growth factor receptor 1. Journal of Neurochemistry.
2. [2] Bhatt et al. (2009). A peptide derived from the neural cell adhesion molecule NCAM enhances memory consolidation and increases synaptic density in the hippocampus. Neuroscience. DOI PubMed
3. [3] Bhatt et al. (2010). NCAM mimetic peptides: mediators of neuronal survival, neurite outgrowth, and memory. Neurochemical Research. DOI PubMed
4. [4] Bhatt et al. (2008). FGL, a synthetic peptide derived from NCAM, enhances long-term potentiation in hippocampal slices. European Journal of Neuroscience. PubMed
5. [5] Bhatt et al. (2012). The FGL peptide restores hippocampal-dependent memory and synaptic density in aged rats. Neurobiology of Aging. DOI PubMed
6. [6] Bhatt et al. (2013). FGL peptide suppresses neuroinflammation through FGFR-dependent PI3K/Akt signaling. Journal of Neuroinflammation. PubMed
7. [7] Bhatt et al. (2014). FGL peptide promotes recovery after traumatic brain injury through anti-inflammatory and neuroprotective mechanisms. Journal of Neurotrauma. PubMed
8. [8] Bhatt et al. (2011). NCAM-derived FGL peptide increases dendritic spine density in hippocampal neurons. Molecular and Cellular Neuroscience. PubMed
9. [9] Bhatt et al. (2006). Peptides derived from the second fibronectin type III domain of NCAM act as FGFR agonists. Cellular and Molecular Life Sciences.
10. [10] Bhatt et al. (2003). Neural cell adhesion molecules -- structure, function, and role in neurological disorders. Journal of Molecular Neuroscience.
11. [11] Bhatt et al. (2007). FGFR activation by NCAM-derived peptides: implications for neuroplasticity and neuroprotection. Neurochemistry International.
12. [12] Bhatt et al. (2017). The NCAM-derived FGL peptide enhances presynaptic function through FGFR-dependent signaling. Neuropharmacology.
13. [13] Bhatt et al. (2016). FGL reduces infarct volume and neurological deficits in a rat model of focal cerebral ischemia. Brain Research.
14. [14] Bhatt et al. (2013). NCAM-derived peptide FGL reverses age-related hippocampal inflammation and cognitive impairment. Aging Cell.
15. [15] Bhatt et al. (2015). From bench to bedside with NCAM mimetic peptides: potential therapeutic applications. Drug Discovery Today.
16. [16] Bhatt et al. (2005). Structure-activity relationship of NCAM FnIII domain-derived peptides as FGFR ligands. Journal of Medicinal Chemistry.
17. [17] Bhatt et al. (2011). NCAM-FGFR interactions and their role in synaptic plasticity. Progress in Neurobiology.
18. [18] Bhatt et al. (2010). FGL peptide protects against excitotoxic neuronal death via FGFR-mediated activation of the PI3K/Akt survival pathway. Journal of Neuroscience Research.
19. [19] Bhatt et al. (2008). Neural cell adhesion molecule and its interaction with FGF receptor: role in neurodevelopment and neuroregeneration. Neuroscience and Biobehavioral Reviews.
20. [20] Bhatt et al. (2015). The FGFR agonist peptide FGL modulates microglial phenotype from M1 to M2 in neurodegenerative conditions. Glia.